PA
RAPP

Parallel Advisors’s Rapport Therapeutics RAPP Stock Holding History

Parallel Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50
Closed -$569 – 3714
2025
Q2 		$569 Buy
+50
New +$531 ﹤0.01% 3291

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parallel Advisors's RAPP Position: Q3 2025 in Review

Parallel Advisors sold out of Rapport Therapeutics (RAPP) in Q3 2025, closing a stake of 50 shares — an estimated $569 sold.

Parallel Advisors first reported a position in RAPP in Q2 2025 and held it in 1 quarter. The position peaked at $569 in Q2 2025. 124 funds tracked by Wall St. Rank hold RAPP as of Q3 2025.

  • Parallel Advisors reported no remaining Rapport Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Parallel Advisors sold 50 Rapport Therapeutics shares in Q3 2025, an estimated $569.
  • Parallel Advisors first reported a position in Rapport Therapeutics in Q2 2025 and held it in 1 quarter.
  • Parallel Advisors's Rapport Therapeutics position peaked at $569 in Q2 2025.
  • 124 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2025.

Based on Parallel Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.